Back to top
more

Merus (MRUS)

(Delayed Data from NSDQ)

$53.34 USD

53.34
396,125

+0.39 (0.74%)

Updated Jul 5, 2024 04:00 PM ET

After-Market: $53.32 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Merus N.V. [MRUS]

Reports for Purchase

Showing records 81 - 100 ( 176 total )

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 81

12/08/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 82

12/08/2020

Company Report

Pages: 5

Do Not Forget to Join Our Webinar with Management Today at 1 PM ET

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 83

11/23/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 84

11/23/2020

Company Report

Pages: 5

Register Now to Join Our Management Webinar on December 8 at 1 pm ET

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 85

11/10/2020

Daily Note

Pages: 16

SITC 2020 Abstract Preview for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 86

11/09/2020

Daily Note

Pages: 20

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 87

11/08/2020

Company Report

Pages: 6

MCLA-158 Ph 1 Update By YE; Zeno Data a Go in 2Q21

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 88

11/08/2020

Company Report

Pages: 6

MCLA-158 Ph 1 Update By YE; Zeno Data a Go in 2Q21

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 89

11/06/2020

Company Report

Pages: 7

All Eyes on eNRGy Trial Update in 2Q21; Reit Buy and $23PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 90

11/06/2020

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 91

11/05/2020

Company Report

Pages: 6

3Q20 - Lead Program Update in 1H21

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 92

09/03/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 93

09/02/2020

Company Report

Pages: 5

COVID-19 Pushes Expected Clinical Data Update from YE2020 to 2Q21

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 94

08/07/2020

Company Report

Pages: 8

eNRGy Trial Powers Foward, Multiple Updates in 2H20; Reit Buy and $23 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 95

08/07/2020

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 96

08/07/2020

Company Report

Pages: 7

2Q20 Financials; Zeno and MCLA-158 Updates Ahead by Year End

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 97

08/07/2020

Company Report

Pages: 6

2Q20 - Expect Clinical Updates by the End of 2020

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 98

08/07/2020

Daily Note

Pages: 20

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 99

07/14/2020

Daily Note

Pages: 4

Caris Collaboration Bodes Well for eNRGy Trial; Reit Buy and $23 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 100

06/26/2020

Company Report

Pages: 61

Biclonics Wage Double-Edged Attack on Cancer; Initiate With Buy and $23 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 150.00

Research Provided by a Third Party